Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

International Journal of Molecular Sciences

Daniela Rau⁴  Michael Lang¹  Andreas Harth²  Markus Naumann³  Frank Weber²  Hayrettin Tumani⁴  Antonios Bayas³ 

[1] Neuropoint Patient Academy, Neurological Practice Center, Ulm 89073, Germany; E-Mail:;Department of Neurology, Military Hospital, Ulm 89081, Germany; E-Mails:;Department of Neurology, Klinikum Augsburg, Augsburg 86156, Germany; E-Mail:;Department of Neurology, University of Ulm, Ulm 89081, Germany; E-Mails:

关键词: alemtuzumab;    multiple sclerosis;    Listeria monocytogenes;    meningitis;   

DOI  :  10.3390/ijms160714669

来源: mdpi

【 摘 要 】

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.